Osamu Hosoya
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 15, 2026
A Cross-sectional Exploratory Study on Symptom Correlations in Multiple Myeloma Patients During Initial Treatment Using the Edmonton Symptom Assessment System.
Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Published: March 01, 2026
Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience.
Journal: British journal of haematology
Published: January 28, 2026
Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma.
Journal: Transplantation and cellular therapy
Published: January 19, 2026
Prognostic significance of cardiac biomarkers in patients with AL amyloidosis treated with a daratumumab-based regimen.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: January 06, 2026
Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS.
Journal: International journal of hematology
Published: September 27, 2025
Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?
Journal: Blood advances
Published: May 16, 2025
Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma.
Journal: Transplant infectious disease : an official journal of the Transplantation Society
Published: February 28, 2025
Efficacy of intensive antiemetic therapy including olanzapine in multiple myeloma patients treated with high-dose melphalan with autologous stem cell transplantation.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: November 08, 2024
Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting.
Journal: Hematological oncology
Published: August 09, 2024
Prognostic value of the "dynamic" R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies.
Journal: Hematological oncology
Published: July 03, 2024
Last Updated: 09/26/2026